Document Detail


Olanzapine/fluoxetine combination for bipolar depression and other mood disorders: a review.
MedLine Citation:
PMID:  16628260     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Patients with bipolar disorder tend to experience most of their illness in the depressed phase. Existing antidepressant therapies are effective in bipolar depression but carry a risk of treatment-emergent mania or increased phase cycling. Other therapies such as lithium may not be particularly effective, or may not currently be licensed for the acute phase, such as lamotrigine. A combination of the antipsychotic olanzapine and the serotonin reuptake inhibitor fluoxetine has been investigated in both bipolar depression and other affective disorders such as psychotic depression and treatment-refractory depression. The combination's possible mode of action, pharmacokinetics, drug interactions, clinical efficacy and safety and tolerability have been reviewed.
Authors:
Richard T Owen
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drugs of today (Barcelona, Spain : 1998)     Volume:  42     ISSN:  1699-3993     ISO Abbreviation:  Drugs Today     Publication Date:  2006 Mar 
Date Detail:
Created Date:  2006-04-21     Completed Date:  2006-08-18     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  101160518     Medline TA:  Drugs Today (Barc)     Country:  Spain    
Other Details:
Languages:  eng     Pagination:  185-92     Citation Subset:  IM    
Copyright Information:
Copyright 2006 Prous Science.
Affiliation:
Medical Information Department, Prous Science, Barcelona, Spain. journals@prous.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antipsychotic Agents / adverse effects,  pharmacokinetics,  pharmacology,  therapeutic use
Benzodiazepines / adverse effects,  pharmacokinetics,  pharmacology,  therapeutic use
Clinical Trials as Topic
Drug Therapy, Combination
Fluoxetine / adverse effects,  pharmacokinetics,  pharmacology,  therapeutic use*
Humans
Mood Disorders / drug therapy*
Serotonin Uptake Inhibitors / adverse effects,  pharmacokinetics,  pharmacology,  therapeutic use
Chemical
Reg. No./Substance:
0/Antipsychotic Agents; 0/Serotonin Uptake Inhibitors; 12794-10-4/Benzodiazepines; 132539-06-1/olanzapine; 54910-89-3/Fluoxetine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ranolazine: focusing on angina pectoris.
Next Document:  Gene therapy for ulcerations of the gastrointestinal tract.